In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors  by Brogi, Simone et al.
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a  b  s  t  r  a  c  t
Plasmodium  falciparum  subtilisin-like  protease  1 (SUB1)  is  a novel  target  for  the  develop-
ment  of innovative  antimalarials.  We  recently  described  the  ﬁrst potent  diﬂuorostatone-based
inhibitors  of  the  enzyme  ((4S)-(N-((N-acetyl-l-lysyl)-l-isoleucyl-l-threonyl-l-alanyl)-2,2-diﬂuoro-3-
oxo-4-aminopentanoyl)glycine  (1)  and  (4S)-(N-((N-acetyl-l-isoleucyl)-l-threonyl-l-alanylamino)-2,2-
diﬂuoro-3-oxo-4-aminopentanoyl)glycine  (2)).  As a continuation  of our  efforts  towards  the  deﬁnition
of the  molecular  determinants  of  enzyme-inhibitor  interaction,  we herein  propose  the  ﬁrst  comprehen-
sive  computational  investigation  of the  SUB1  catalytic  core  from  six  different  Plasmodium  species,  using
homology  modeling  and  molecular  docking  approaches.  Investigation  of  the  differences  in the binding
sites  as  well  as  the  interactions  of  our inhibitors  1,2  with all SUB1  orthologues,  allowed  us  to  highlight  the
structurally  relevant  regions  of the enzyme  that  could  be  targeted  for developing  pan-SUB1  inhibitors.iﬂuorostatone-based inhibitors
harmacophore modeling
According  to  our in silico  predictions,  compounds  1,2  have  been  demonstrated  to  be  potent  inhibitors  of
SUB1 from  all  three  major  clinically  relevant  Plasmodium  species  (P. falciparum,  P. vivax,  and  P.  knowlesi).
We  next  derived  multiple  structure-based  pharmacophore  models  that were  combined  in  an  inclusive
pan-SUB1  pharmacophore  (SUB1-PHA).  This  latter  was  validated  by applying  in  silico  methods,  showing
that  it  may  be useful  for the  future  development  of potent  antimalarial  agents.
© 2016 Elsevier  Inc.  All  rights  reserved.. Introduction
Several Plasmodium species cause malaria in humans. Among
hem, P. falciparum is the etiological agent of the most deadly form
f malaria. As a consequence, much attention has been devoted
o the search for novel drugs for treating P. falciparum infections.
. vivax has historically been considered relatively avirulent com-
ared to P. falciparum,  so development of new chemotherapies
gainst P. vivax has been relatively neglected [1]. However, mor-
idity due to P. vivax infection contributes to most of the social
nd economic burden of malaria outside Africa, and infections are
∗ Corresponding authors at: European Research Centre for Drug Discovery and
evelopment (NatSynDrugs), University of Siena, via Aldo Moro 2, 53100 Siena,
taly. Fax: +39 0577 234254.
E-mail addresses: gemma@unisi.it (S. Gemma), campiani@unisi.it (G. Campiani).
ttp://dx.doi.org/10.1016/j.jmgm.2016.01.005
093-3263/© 2016 Elsevier Inc. All rights reserved.complicated by relapses that can occur as much as 2 years follow-
ing primary infection. In addition, it is now recognized that human
infections by the zoonotic pathogen P. knowlesi are widespread
in areas of South-East Asia [2]. Malaria caused by P. knowlesi can
be severe and often fatal, so development of diagnostic tools and
speciﬁc chemotherapies is urgently required. The P. falciparum
subtilisin-like protease 1 (PfSUB1) is a serine protease which plays
a key role in both egress of merozoites from infected erythrocytes
and priming the developing merozoites for invasion of new ery-
throcytes [3–6]. This enzyme also plays an essential role in the
development and egress of hepatic merozoites [7,8]. Drugs based on
inhibitors of SUB1 could overcome the issue of resistance to chloro-
quine and several other currently available antimalarials, as well
as the emerging resistance of P. falciparum to artemisinins [9,10].
Moreover, the same approach can be exploited for the develop-
ment of new chemotherapeutics against P. vivax and P. knowlesi,
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Fig. 1. Diﬂuorostatone-based inhibitors 1 (4S)-(N-((N-acetyl-l-lysyl)-l-isoleucyl-
l-threonyl-l-alanyl)-2,2-diﬂuoro-3-oxo-4-aminopentanoyl)glycine) and 2
((4S)-(N-((N-acetyl-l-isoleucyl)-l-threonyl-l-alanyl amino)-2,2-diﬂuoro-3-
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residues of our reﬁned SUB1 models sit in the allowed regions of
the Ramachandran Plot. This value is higher than the cut-off valuexo-4-aminopentanoyl)glycine).
hich express orthologous SUB1 enzymes [11]. It is worth noticing
hat, differently from other drug targets in malaria in which rapid
election of mutants was observed (e.g., cytochrome b targeted by
tovaquone [12–15]), PfSUB1 represents a particularly excellent
rug target because the likelihood of simultaneous compensatory
utations in both the protease active site and the substrate cleav-
ge sites that might result in drug resistance is low. Endogenous
ubstrates of PfSUB1 have been investigated and some studies ana-
yzing in silico the interaction of peptides based on endogenous
equences with PfSUB1 and PvSUB1 have been previously in depth
nalyzed [6,11,16–18]. Few PfSUB1 or PvSUB1 inhibitors have been
escribed to date [11,16,19,20]. We  recently developed the ﬁrst
otent diﬂuorostatone-based inhibitors (1 and 2, Fig. 1) of PfSUB1
21] and we later in depth analyzed the structure-activity relation-
hips (SARs) for this series of compounds [22]. In this context, our
lan is the development of pan-inhibitors that may  represent an
nnovative approach for treating infections caused by the human
alaria pathogens.
Towards this ambitious aim, we decided to dissect the similar-
ties between the SUB1 orthologues from all three major human
alaria pathogens in order to ascertain the likelihood of develop-
ng a single inhibitor for all three enzymes. We  here describe the
evelopment of a homology model of the active core of PkSUB1,
nd the comparison of the structural features of its binding site
left with the crystal structures of PvSUB1 [23] and PfSUB1 [24]. To
xpand the scope of our investigation, we also developed homology
odels of SUB1 from P. berghei, P. chabaudi, and P. yoelii, three Plas-
odium species that speciﬁcally infect rodents and are routinely
sed for testing antimalarial compounds in vivo. It has been pre-
iously demonstrated that the PbSUB1 active site is signiﬁcantly
ifferent from that of PfSUB1 [11], so we extended our investiga-
ion to PcSUB1 and PySUB1. Moreover we have updated the PbSUB1
odel previously described [11] using the experimentally solved
fSUB1 and PvSUB1 crystal structures as templates. The overall
bjective of the work here described is the analysis of the binding
ode of our diﬂuorostatone-based inhibitors to the six ortholo-
ous enzymes in order to: (i) assess the feasibility of a pan-inhibitor
ctive against all three clinically relevant parasites; (ii) derive and
alidate a pharmacophore model to be used as design tool for the
ynthesis of pan-inhibitors and/or in a virtual screening campaign
o identify novel chemical entities able to inhibit SUB1s, and (iii)
erify the possibility of using the rodent malarial parasites as mod-
ls to assess the efﬁcacy of inhibitors designed on the basis of the
uman clinically relevant parasites.s and Modelling 64 (2016) 121–130
2. Materials and methods
2.1. Diﬂuorostatone-based inhibitors
Compounds 1 and 2 were synthesized following a previously
described synthetic procedure [21] and were tested against Pv- and
Pk-SUB1 as described in Paragraph 2.7.
2.2. Computational details
All the calculations performed in this work were carried out
on three Cooler Master Centurion 5 (Intel Core2 Quad CPU Q6600
@ 2.40 GHz; Intel Core i5–2400CPU @ 3.10 GHz Quad; Intel Core
i5–2500CPU @ 3.30 GHz Quad) with Ubuntu 10.04 LTS (long-term
support) operating system running Maestro 9.2 (Schrödinger, LLC,
New York, NY, 2011) and GOLD software (version 5.2, Cambridge
Crystallographic Data Center, UK, 2013).
2.3. Homology modeling of SUB1
The sequence of SUB1s were taken in fasta format from UniPro-
tKB [25] (PbSUB1 UniprotKB code: Q4YVE1; PySUB1 UniprotKB
code: Q7RGL7; PcSUb1 UniprotKB code: Q4XWG6; PkSUB1 Unipro-
tKB code: B3L6J4). The SUB1 homology models were built using
the recently published PfSUB1 and PvSUB1 crystal structures (PDB
codes: 4LVN and 4TR2, respectively) [23,24], applying multiple
template-based alignment as previously reported by us [21,26,27].
The sequence identity found by Prime during the template selec-
tion step for PbSUB1 were 4LVN 64%, 4TR2 58%; for PySUB1 were
4LVN 64%, 4TR2 58%; for PcSUB1 were 4LVN 67%, 4TR2 57%; and for
PkSUB1 were 4LVN 75%, 4TR2 80%. In order to model the core cat-
alytic domain of SUB1 orthologues Prime software [28] was  used.
Homology models were generated using the above-mentioned
templates. These templates aligned to each query sequence were
used for “Comparative Modeling” methods implemented in Prime.
Since Prime offers several ways to build a model, we speciﬁed in
the “build structure step” the method used for aligning multiple
templates of all the SUB1 structures. Consensus model option was
employed to build the model; this option allowed us to take into
account all the previously selected templates since the model was
built as an average of all templates. Each predicted SUB1 model
for each different Plasmodium species was  reﬁned by means of
Prime software by side-chain optimization and loop reﬁnement.
Further structure optimization was  carried out using the Macro-
Model (MacroModel, version 9.9, Schrödinger, LLC, New York, NY,
2011) application implemented in Maestro suite 2011 using the
Optimized Potentials for Liquid Simulations-all atom (OPLS-AA)
force ﬁeld 2005 with 10,000 maximum iterations and 0.001 as
convergence threshold using PRCG method [29,30].
The quality of modelled proteins was assessed by means
of Ramachandran plots generated by the RAMPAGE webserver
(http://mordred.bioc.cam.ac.uk/∼rapper/rampage.php accessed
date May  2015) [31]. For all the modelled SUB1, around 95% of the
protein residues lie in the favoured region of the plot, around 4%
lie in the additional allowed region and less than 0.6% (amino acids
not involved in the binding site) of the residues were located in the
disallowed regions. As previously found for the PfSUB1 homology
model [21] the other generated SUB1 3D structures displayed a
satisfactory and similar stereochemical quality. Accordingly, the
results of the RAMPAGE webserver revealed that over 99% of the(96.1%) deﬁned for the most reliable models [32]. Consequently,
the stereochemical quality of our SUB1 homology models was
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cceptable, displaying a very low percentage of residues having
hi/psi angles in outlier regions.
.4. Molecular docking protocol
.4.1. Ligand preparation
Three-dimensional (3D) structure building for all compounds in
his study was  carried out using Maestro 9.2 (Schrödinger, LLC, New
ork, NY, 2011). The stereochemistry of compounds was taken into
ccount according to Fig. 1. Molecular energy minimizations were
erformed in MacroModel using the Optimized Potentials for Liq-
id Simulations-all atom (OPLS-AA) force ﬁeld 2005. Solvent effects
ere simulated using the analytical Generalized-Born/Surface-
rea (GB/SA) model [33], and no cutoff for nonbonded interactions
as selected. Polak-Ribiere conjugate gradient (PRCG) method
ith 1000 maximum iterations and 0.001 gradient convergence
hreshold was employed [34]. All the compounds reported in
his paper were treated by the LigPrep application (version 2.5,
chrödinger, LLC, New York, NY, 2011), implemented in Maestro
uite 2011, generating the most probable ionization state of any
ossible enantiomers and tautomers at cellular pH values (7 ± 0.5).
.4.2. Protein preparation
The SUB1 homology models and crystal structures were
mported into Schrödinger Maestro molecular modeling environ-
ent (Maestro, version 9.2; Schrödinger, LLC: New York, 2011).
or the crystal structures all the water molecules and the chemi-
als used for the crystallization procedure were removed. Resulting
rystal structures and homology models were submitted to the pro-
ein preparation wizard workﬂow implemented in Maestro suite
011 (Protein Preparation Wizard workﬂow 2011; http://www.
chrodinger.com/supportdocs/18/16). This protocol allowed us to
btain a reasonable starting structure of proteins for molecular
ocking calculations by a series of computational steps. In particu-
ar, we performed three steps to [1] add hydrogens, [2] optimize
he orientation of hydroxyl groups, Asn, and Gln, and the pro-
onation state of His, and [3] perform a constrained reﬁnement
ith the impref utility, setting the max  RMSD of 0.30. The impref
tility consists of a cycle of energy minimization based on the
mpact molecular mechanics engine and on the OPLS 2005 force
eld [29,30].
.4.3. Molecular docking
Molecular Docking studies were carried out using GOLD 5.2
Genetic Optimization for Ligand Docking) software from the Cam-
ridge Crystallographic Data Center, UK, that uses the Genetic
lgorithm (GA) [35]. This method allows a partial ﬂexibility of pro-
ein and full ﬂexibility of ligand. For each of the 100 independent
A runs, a maximum number of 125000 GA operations were per-
ormed. The search efﬁciency values were set at 200% in order to
ncrease the ﬂexibility of the ligands docked. As reported in the
OLD user manual this parameter is recommended for large, highly
exible ligands. The active site radius of 8 Å was  chosen by XYZ
oordinates from the center of the catalytic triad, considering the
atalytic Ser as previously described [21]. Default cutoff values of
.5 Å (dH-X) for hydrogen bonds and 4.0 Å for van der Waals dis-
ance were employed. When the top three solutions attained RMSD
alues within 1.5 Å, GA docking was terminated. The ﬁtness func-
ion GoldScore [36] was evaluated. All the poses herein presented
re representative of the most populated clusters of docked solu-
ions, and were chosen after cluster analysis and visual inspection..5. Structure-based pharmacophore generation
The 1-SUB1 and 2-SUB1 complexes (PfSUB1, PvSUB1 and
kSUB1) were employed for structure-based (SB) pharmacophores and Modelling 64 (2016) 121–130 123
generation by means of the e-Pharmacophore application (Maestro,
version 9.2, Schrödinger, LLC, New York, NY, 2011). The outputs
obtained by means of GOLD software were considered as the start-
ing structures for SB pharmacophore generation. Compounds 1 and
2 were extracted from the enzymes and re-docked into the respec-
tive binding site using Glide software [37] applying rigid docking
and using the score in place method to preserve the original con-
formation previously found. For this latter, Glide XP was  used and
the grid was generated with default settings using compound 1
as reference ligand. Subsequently, 1 and 2 were re-docked in the
same conformation derived from the complex generated by GOLD
software using Glide extra precision (XP) method by using the
score in place method to preserve the original poses. Following
this method, it was possible to generate a .Xpdes ﬁle contain-
ing the protein–ligand interaction data, necessary for developing a
SB pharmacophore by means of e-Pharmacophore. The Glide pose
was selected and used in e-Pharmacophore GUI. The ligand mode
option was used to develop a pharmacophore hypothesis. The max-
imum feature option was set to 10, with a minimum inter-feature
distance of 2.0 Å. Receptor-based excluded volumes were created
using 0.5 as van der Waals scaling factor. Pharmacophore sites were
automatically generated from the protein–ligand docked complex
with Phase using the default set of six chemical features: hydro-
gen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H),
negative ionizable (N), positive ionizable (P), and aromatic ring (R)
[38], no user-deﬁned features were employed in this study. The e-
Pharmacophore hypothesis was imported and managed into Phase
according to docking studies. The obtained SB pharmacophores are
shown in Fig. 6. The most conserved features among SB pharma-
cophores were clustered by Phase according to common features
pharmacophore hypothesis generation. The resulting SB hypoth-
esis (SUB1-PHA) consists of six features: three hydrogen-bond
acceptors (A1, A2, and A3; represented by red vectors), one bond
donor (D2; represented by light blue vectors), one hydrophobic
function (H1; represented by a green sphere) and one negative
ionizable centre (N1; represented by a dark red sphere). The inter
features distance of AAADHN hypothesis is reported in Fig. 7. The
ﬁtness of all compounds was  calculated by Phase by applying the
SUB1-PHA model, employing excluded volumes, and using search
for matches option. The conformers were generated by means of
ConGen (ConfGen, version 2.3, Schrödinger, LLC, New York, 2011)
during the “search for matches” calculations.
2.6. Pharmacophore validation
Database of Useful Decoys: Enhanced (DUD-E) web  server
(http://dude.docking.org access date May  2015) was  used to gen-
erate a set of decoys starting from our active compounds 1, 2 and
other unique substrate-based SUB1 inhibitors for the selected Plas-
modium species, represented by KS-182 (3) and KS-466 (4) and
reported in literature [11] (Table S1). Peptidyl -ketoamide 3 (Table
S1) showed lower inhibitory potency against the PfSUB1, PkSUB1
and PvSUB1 (IC50 values: 6 M,  6 M and 12 M, respectively) than
compounds 1 and 2 (Fig. 1), while 4 (Table S1) showed an IC50
value comparable to 1 and 2 (PfSUB1, PkSUB1 and PvSUB1 IC50
values: 1 M,  1 M and 2 M,  respectively) [11]. It is worth notic-
ing that these compounds were tested in the same condition of
inhibitors 1 and 2. For the active ligands DUD-E server provided
169 inactive ligands (redundant structures in the output ﬁles were
delete) from a subset of the ZINC database (http://zinc.docking.org
accessed date May  2015) ﬁltered using the Lipinski rules for drug-
likeness, for a total of 173 compounds between active and inactive
(Table S1). Each of these inactive decoys is chosen to resemble the
reference ligand physico-chemical properties but to have differ-
ent 2D structure (e.g., very large difference of Tanimoto coefﬁcient
between active molecules and decoys). After the generation, the
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Table 1
Sequence comparison of PbSUB1 (UniprotKB code: Q4YVE1; 562 aa),
PySUB1(UniprotKB code: Q7RGL7; 599 aa), PcSUb1 (UniprotKB code: Q4XWG6;
581 aa), PvSUB1 (UniprotKB code: E6Y8B9; 630 aa), and PkSUB1 (UniprotKB code:
B3L6J4; 638 aa) with PfSUB1 (UniprotKB code: Q8I0V0; 688 aa).
SUB1s Sequence identitya Identical residuesa Similar residuesa Core identityb
PbSUB1 49.2% 339 156 64%
PySUB1 49.7% 345 172 64%
PcSUB1 48.5% 334 181 67%
PvSUB1 55.0% 380 161 74%
PkSUB1 55.3% 382 164 75%
a The calculation was  performed by Clustal omega provided by the Uniprot web-
site (http://www.uniprot.org/align).
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Table 2
IC50 (M) of SUB1 inhibitors 1 and 2.
Compound PfSUB1a PkSUB1 PvSUB1
1 0.60 1.12 2.5b The core of PfSUB1 lies between F338 and K669 as determined from the crystal
tructure [42]. The calculation was  performed by ClustalW implemented in Prime
.0.
ecoys sets were downloaded as four smiles ﬁles and imported into
aestro in order to perform a minimization by means of Macro-
odel (the same parameters reported for ligand preparation were
pplied). Furthermore, before submitting the obtained set of decoys
o ﬁtness evaluation, LigPrep application was used to prepare the
igands for removing potential erroneous structures and for assess-
ng the stereochemistry of the active compounds. Notably, by visual
nspection of selected decoys, we found that a relevant number
f generated decoys (about 25%) maintained a signiﬁcant peptidic
haracter. A single ﬁle containing active molecules and decoys was
reated and submitted to Phase for evaluating the ﬁtness against
he SUB1-PHA. After decoys generation and pharmacophore ﬁtness
valuation enrichment factor (EF) value, Güner and Henry score,
.e., goodness of hit-list (GH) were calculated by the Eqs. (1) and
2), respectively.
F = Ha/Ht
(A/D)
(1)
H =
{
Ha × (3A + Ht)
4HtA
}
×
[
1 − (Ht − Ha)
(D − A)
]
(2)
here Ht is the total number of molecules in the hit list found by
harmacophore screening (ﬁtness cutoff 2.00), Ha represents the
otal active molecules found by screening applying a ﬁtness cutoff
alue of 2.00, A is the total of the active molecules present in the
atabase, while D is the total molecules present in the set. The range
f GH score varies from 0 to 1. GH score 0 means a null model,
hile the GH score 1 means generation of an ideal model. Moreover,
lso the % yield of actives (%YA) and % ratio of actives (%RA) were
valuated by the Eqs. (3) and (4), respectively.
YA =
[(
Ha
Ht
)
× 100
]
(3)
RA =
[(
Ha
A
)
× 100
]
(4)
Results concerning the pharmacophore validation are provided
n the Section 3 (Table 3) and in Table S1 in the Supplementary
aterial.
.7. SUB1 inhibition assays for IC50 determination
Inhibitory potency of compounds 1 and 2 against recombinant
fSUB1, PkSUB1 and PvSUB1 [11,24] was assayed as previously
escribed [5,6,11], using ﬂuorogenic substrate SERA4st1F-6R12,
hich is peptide Ac-CKITAQDDEESC labelled on both cysteine side-
hains with tetramethylrhodamine. The intact substrate displays
ow ﬂuorescence due to non-covalent, concentration-dependent
imerization of the rhodamines. Cleavage within the peptide back-
one allows dissociation of the rhodamine dimer and consequent
uorescence increase. One unit (1 U) of recombinant PfSUB1 is2  0.60 0.68 2.2
a IC50 values as presented in Ref. [3].
deﬁned as the amount of protease that hydrolyses 1 pmol of
SERA4st1F-6R12 in 1 min  at a substrate concentration of 0.1 M
in digestion buffer (25 mM  Tris-HCl pH 8.2, 12 mM CaCl2, 25 mM
CHAPS) at 21 ◦C. For kinetic assays to determine IC50 values for test
compounds, wells of a 96-well white microplate (Nunc) containing
48 L puriﬁed enzyme (∼1 U/mL in digestion buffer), were supple-
mented in triplicate with 2 L of various concentrations of the test
compounds, freshly diluted in dry DMSO, prior to addition of 50 L
substrate (0.1 M in digestion buffer). The resulting ﬂuorescence
increase was continuously monitored with time at 21 ◦C using a
Cary Eclipse ﬂuorescence spectrophotometer (Varian) equipped
with a 96-well microplate reader accessory. Initial hydrolysis rates
calculated from the resulting progress curves were plotted against
test compound concentration to obtain IC50 values. Vehicle alone
(DMSO) was  used to obtain values for uninhibited enzyme activity
and para-hydroxymercuribenzoate, a potent inhibitor of SUB1 [24],
was used as a positive control inhibitor.
3. Results and discussion
Our computational investigation started by comparing the con-
served regions of the catalytic domains of the SUB1 orthologues.
To examine the degree of sequence homology within the binding
core of the enzymes, the primary structures of all SUB1 proteases
were obtained from the UniprotKB database and aligned with the
PfSUB1 sequence previously investigated by us [21] (Fig. 2).
Although the alignment (Fig. 2 and Table 1) demonstrated a
high degree of conservation of residues located around the catalytic
triad, important differences in the binding sites of SUB1 ortho-
logues were observed. We  therefore generated, through homology
modeling, the 3D structures of the catalytic cores of SUB1 ortho-
logues for which the crystal structure is not available. Our original
PfSUB1 homology model was developed by adopting a multiple
template-based approach [11,21,26,27], which allowed us to dis-
cover the most potent PfSUB1 inhibitors reported to date, namely
1 and 2 (Fig. 1) [21]. This methodology resulted in an improved
quality of the ﬁnal 3D-homology models [39–41]. For the present
study, we adopted multiple template-based alignment technique
using the PfSUB1 [24] (PDB code: 4LVN) and PvSUB1 [23] (PDB
code: 4TR2) crystal structures as templates to build 3D models
of the other SUB1 orthologues (see Section 2). As expected, the
above-mentioned experimental structures showed a high degree
of identity and similarity within the SUB1 orthologues (see homol-
ogy modeling paragraph). The third top-ranking template (bacterial
collagenolytic serine protease PDB code: 3VV3) had a dramatically
lower degree of core identity (core region: PbSUB1 38%; PcSUB1
39%; PySUB1 38%; PkSUB1 37%; the percentage of identity was
calculated by Prime [28] during template selection step).
By comparing the sequences and by superposing the 3D mod-
els of PbSUB1 (Fig. 3), PcSUB1 (Fig. S1) and PySUB1 (Fig. S2) on
that of PfSUB1, we identiﬁed relevant differences in the putative
active sites of these orthologues. In particular, as exempliﬁed in
Fig. 3A for PbSUB1, the most relevant differences from PfSUB1 are
located in the S’ surface (replacement of PfSUB1 residues N603,
K601, R600 by PbSUB1 residues S479, E477, M476, respectively),
the S2 pocket (replacement of PfSUB1 residues Y427, N426 by N304,
H303), and the S3 sub-site (PfSUB1 residue M472 replaced by I349
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Fig. 2. Multiple alignments between complete sequences of PfSUB1, PbSUB1, PcSUB1, PkSUB1, PvSUB1 and PySUB1. The intensity of the purple shading indicates the degree
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as  generated using jalview implemented in the EMBL-EBI website (https://www.e
s  referred to the web version of this article.)
n PbSUB1). A similar result was obtained for PcSUB1 and PySUB1
hen compared to PfSUB1 (Fig. S1 and S2, respectively).
In contrast, a comparison of PvSUB1 and PkSUB1 with PfSUB1
Fig. 3B and Fig. S3, respectively) showed that the binding sites
re superimposable, with PfSUB1 K541 and S522 residues replaced
y R485 and A466 in PvSUB1, and only K541 replaced by R494 in
kSUB1. These amino acids replacements only marginally inﬂuence
ubstrate binding, since they are located at the edge of the binding
ites.
We next applied an intensive molecular docking protocol using
he SUB1 crystal structures and homology models to investigate the
inding modes of 1 and 2 (Fig. 1). Molecular docking was carried
ut using GOLD software, applying Goldscore as scoring function
35,43] (see Section 2 for further details). Since inhibitors 1 and 2
ere designed on the basis of a PfSUB1 endogenous substrate, we
nvisaged different recognition patterns of these inhibitors in com-
lex with PbSUB1, PcSUB1 and PySUB1, while we  expected similar
inding modes for 1 and 2 when docked into PvSUB1 and PkSUB1.
As previously described [21], the output of docking calcula-
ions reveals that compound 1 in complex with PfSUB1 (Fig. 4A)
s engaged in H-bonding with S492, S519, G467, and H428, while
465 is able to form a H-bond with the carbonyl group of the diﬂu-
rostatone amide. The free acidic functionality of 1 establishes a
eries of polar contacts with R600, Y427 and K465. The formation
f these polar contacts, along with the favorable binding confor-nce. Residues included in the binding sites were rounded by a red line. The image
uk/). (For interpretation of the references to colour in this ﬁgure legend, the reader
mation of 1, allows the diﬂuorostatone electrophilic carbon of the
carbonyl group (described in [21]) to lie in the proximity of the cat-
alytic S606 (5.0 Å) and accounts for its high binding score (93.56).
The calculated values highlighted the high afﬁnity of 1 for PfSUB1.
A similar output was found for inhibitor 2 (Fig. S4). Analogously,
due to the similarities in SUB1 binding sites, 1 and 2 are expected
to bind tightly to PvSUB1 and PkSUB1.
The molecular docking calculation of 1 into the PvSUB1 binding
site (Fig. 4B) is similar to that found for 1 in PfSUB1 (docking of 2
into PvSUB1 is reported in Fig. S5). Compound 1 occupies the full
length of the cleft and strongly interacts with both the S′ and S2
regions through its P1′ and P1 moieties, respectively (Fig. 4B).
In particular, a network of H-bonds with Y371 and K409 is
formed, analogous to that observed in the PfSUB1 structure. The
targeted residue K409 (K465 in PfSUB1) appears critical for enzyme
inhibition [24]. Importantly, the electrophilic carbon of the diﬂu-
orostatone carbonyl group lies 5.7 Å from the catalytic S549. In
addition compound 1 appeared able to directly interact with oxyan-
ion hole by H-bonding with N464. Further contacts were detected
with a central residue of the S1 pocket (S436). Notably, the P4
residue of 1 is accommodated into the hydrophobic S4 region as
found for PfSUB1, allowing contacts with G411. The Goldscore of 1
in PvSUB1 (84.89) is slightly lower than that of 1 in PfSUB1 (93.56).
Based on this data we expect that 1 should be able to inhibit PvSUB1
with a potency similar to PfSUB1. A similar output was also found
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Fig. 3. Superposition between the binding sites of PbSUB1 and PvSUB1 catalytic
core with PfSUB1. A) Superposition between binding sites of the PbSUB1 homology
model (magenta sticks) and the PfSUB1 crystal structure (cyan sticks) (PDB code
4LVN). Catalytic triad residues (His, Ser, Asp) are represented by lines. The num-
bering of PbSUB1 is in agreement with the sequence obtained from UniprotKB. B)
Superposition between catalytic core of the PvSUB1 crystal structure (PDB code
4TR2) (yellow sticks) and the PfSUB1 crystal structure (PDB code 4LVN). Catalytic
triad residues (His, Ser, Asp) are represented by lines. All hydrogens are removed for
clarity. The picture was  generated by PyMOL (The PyMOL Molecular Graphics Sys-
tem,  v1.6-alpha; Schrodinger LLC, New York, NY, 2013). (For interpretation of the
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Fig. 4. Docking of 1 in PfSUB1 and PvSUB1. A) Docked pose of 1 (pink sticks) into
the PfSUB1 crystal structure binding site (PDB code 4LVN) [21]. B) Docked pose of
1  (pink sticks) into the PvSUB1 binding site (PDB code 4TR2) (yellow sticks). Key
residues are represented by sticks, while the catalytic triad is represented by lines
(H428, S606, and D372 for PfSUB1; H372, S549, and D316 for PvSUB1). Non-polar
hydrogens are removed for clarity. H-bonds are represented by black dotted lines.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 5. Docked pose of 1 (yellow sticks) into the PbSUB1 homology model binding
site (magenta sticks). Key residues are represented by sticks, while the catalytic triadeferences to colour in this ﬁgure legend, the reader is referred to the web  version
f  this article.)
or 1 when docked into PkSUB1 (Fig. S6). The results for 2 in PkSUB1
re provided in the Supplementary material (Fig. S7).
Gratifyingly, the predicted afﬁnities of 1 and 2 for PvSUB1 and
kSUB1 were supported by experimental data (Table 2). In fact,
oth inhibitors 1 and 2 showed comparable inhibitory potencies
hen tested against the target enzymes, conﬁrming that, concern-
ng clinically relevant Plasmodium species, 1 and 2 are pan-SUB1
nhibitors.
On the other hand, signiﬁcant dissimilarities were found among
he predicted binding modes of 1 and 2 when docked into PbSUB1,
cSUB1 and PySUB1 in comparison with the binding modes in
fSUB1, PvSUB1 and PkSUB1. The docking of 1 into the PbSUB1
inding site is shown in Fig. 5, while the other docking results,
amely 2 with PbSUB1 (Fig. S8), 1 with PcSUB1 and PySUB1 (Fig. S9
nd S10, respectively) and 2 with PcSUB1 and PySUB1 (Figs. S11 and
12, respectively) are presented in the Supplementary material.
The docking calculation for 1 into the PbSUB1 binding site (Fig. 5)
evealed that 1 is unable to correctly interact with the catalytic
is  represented by lines (H305, S482, and D249). Non-polar hydrogens were removed
for clarity. H-bonds are represented by black dotted lines. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version
of  this article.)
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Fig. 6. Features of the SB-pharmacophores and their superposition. (A–C) SB pharmacophores obtained for PfSUB1, PvSUB1 and PkSUB1, respectively with compound 1. (D)
Conserved features among the six SB pharmacophores highlighted by color-coded circles. The yellow spheres represent the excluded volumes. H-bonds are represented by
black  dotted lines. Pictures were generated by means of Maestro. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web  version
of  this article.)
Fig. 7. SUB1-PHA (inter features distance: N1–A1 4.10 Å; A1–A2 9.17 Å; N1-D2 13.91 Å; A2–A3 6.50 Å; A2–H1 5.61 Å; D2–A3 5.25 Å; D2–H1 4.19 Å; A3–H1 4.12 Å; N1–A1–A2 angle
123.1◦) implemented with SUB1 recognition sites (S′-S4) highlighting the conserved target residues for all the enzymes taken into account coupled to SiteMap outputs (the
m rface:
t ased 
m
t
c
taps  of binding sites for a potential ligand interaction are represented as a solid su
he  comprehensive excluded volume. The catalytic triad (Ser-His-Asp) is depicted b
eans  of Maestro.riad. In particular, the distance of the diﬂuorostatone electrophilic
arbonyl carbon from the catalytic Ser (S482) is 11.8 Å (compared
o 5.0 Å from S606 in the PfSUB1 binding site). red = acceptor; blue = donor; yellow = hydrophobic). The yellow spheres represent
on the superposition of PfSUB1, PvSUB1 and PkSUB1. The image was generated byMoreover, 1 establishes a smaller number of contacts with
PbSUB1, forming only three H-bonds with K372, S479 and S369.
Due to the differences between PfSUB1 and PbSUB1 in the amino
acid composition of the S1′ and S4 sub-sites, 1 does not project
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d 2 (Panel B). The pictures were generated by means of Maestro.
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Table 3
EF and GH scores obtained by the application of SUB1-PHA in a database screening.
Parameters Values
Total molecules in database (D) 173
Total number of actives in database (A) 4
Total hits (Ht) 5
Active hits (Ha) 3
%  Yield of actives (YA) 0.60
%  Ratio of actives (RA) 0.75Fig. 8. Superposition among SUB1-PHA and 1 (panel A) an
nto the PbSUB1 S4 region nor into the S1′ sub-site, so its car-
oxylic acid moiety cannot create the key contacts observed for
fSUB1. Based on the observed binding mode, we can predict a
ower inhibitory potency for 1 against all three murine malaria
arasite SUB1 orthologues. Accordingly, the Goldscore found for
 in PbSUB1 is substantially lower (67.19) than that for 1 in PfSUB1
93.56). These predictions are in agreement with the experimental
ata on PbSUB1 obtained for other PfSUB1 inhibitors designed on
he basis of the endogenous substrate [11]. The analogous results
or 2 in PbSUB1 are presented in Fig. S8. Similar bindings have been
redicted for 1 in PcSUB1 and PySUB1 (the GoldScore of 1 in PcSUB1
s 67.81 and in PySUB1 is 71.70) and are provided in Fig. S9 and
10, respectively (results for compound 2 in PcSUB1 and PySUB1
re reported in Fig. S11 and S12, respectively). These ﬁndings fully
upport the key role of the S′ region in SUB1-ligand recognition in
he human malaria pathogen enzymes.
Based on the docking analysis of 1 and 2 in complex with PfSUB1,
vSUB1 and PkSUB1, we developed a comprehensive pharma-
ophore useful for the rational design of pan-SUB1 inhibitors. For
enerating a multiple SB pharmacophore, we took into account our
nowledge in pharmacophore modeling by using Phase [27,44–47],
nd the e-Pharmacophore protocol [27]. This procedure combines
harmacophore perception with protein ligand energetic terms
omputed by the Glide XP (extra precision) scoring function (see
xperimental section for details) that improves the reliability of
he 3D pharmacophores.
The poses obtained by the classical docking calculations
escribed in the previous paragraphs were used to generate a
B pharmacophore for each SUB1 orthologue through the e-
harmacophore application. Superposition between 1 and SB
harmacophore models is shown in Fig. 6A–C (PfSUB1, PvSUB1 and
kSUB1 respectively); for compound 2, pharmacophore modeling
tudies are provided in Fig. S13. The multiple SB pharmacophores
ere then analyzed and the common features were clustered in
rder to obtain a comprehensive pharmacophore model (Fig. 6D).
his model takes into account the information derived from the
etrieved binding modes coupled to binding energetic terms. The
odel was further elaborated by employing the SiteMap output
epicted in Fig. 7. This model represents the ﬁrst comprehensive
UB1-pharmacophore (SUB1-PHA) containing all the necessary
eatures that a molecule must possess in order to inhibit all three
UB1 orthologues under consideration. As reported in Fig. 7, the
UB1-PHA consists of six features: three hydrogen-bond acceptors
A1, A2, and A3; represented by red vectors), one hydrogen-bond
onor (D2; represented by light blue vectors), one hydrophobic
unction (H1; represented by a green sphere) and one negatively
onizable centre (N1; represented by a dark red sphere). In par-Enrichment factor (EF) 25.95
Goodness of hit score (GH) 0.63
ticular, features N1 and A1 are essential for interacting through
the polar S’ and S2 sub-pockets with conserved Arg, Tyr and Lys
residues respectively. The A2 and D2 features are essential for estab-
lishing polar contacts with the central recognition site (S1) with
conserved Ser, Phe (backbone) as well as with Asn (oxyanion hole)
residues. Feature A3 was found to be important for interacting at the
S3 site with a conserved Gly. Moreover, the hydrophobic function
H1 is required to interact at the S4 in the conserved hydropho-
bic sub-pocket formed by three Phe residues and a Leu as already
highlighted by us 21. SiteMap outputs provide information about
the polar/hydrophobic requirements for the linker connecting the
selected features.
Next, we performed a preliminary in silico validation of our
SUB1-PHA using a pharmacophore validation method based on the
generation of decoys set, a procedure largely used to assess the
ability of pharmacophore models to discriminate between active
or inactive molecules [48–58]. Starting from compounds 1 and 2
(superposed to the SUB1-PHA in Fig. 8), and literature compounds
3 and 4 (KS-182 and KS-466, respectively) [59] we generated 169
decoys by means of DUD-E server [60,61] (see Experimental Section
for further details about the selection of active compounds). So, the
database consists of 173 compounds (D) including 4 known active
molecules (A) (Table 3). The database screening results (Table 3 and
Table S1) showed that 5 molecules were found as hits (Ht) apply-
ing a ﬁtness cutoff value of 2.00 (this value could represent the
lower limit to consider a molecule as active). Among these, 3 com-
pounds (Ha) belong to the four known inhibitors (1,2 and 4, the only
compounds able to match all the pharmacophore sites).
Compound 3 was ranked 9th, matching ﬁve SUB1-PHA sites.
Concerning the ﬁtness estimation of decoys set (Table S1), it is
well evident the inability for the inactive compounds to match all
the features of SUB1-PHA as highlighted by small values of ﬁtness
(all decoys matched 3–5 features, but none of them matched all
SUB1-PHA features). It is also worth noticing that around 25% of
decoys presented a peptidic character. The EF was calculated to be
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5.95, which means that is 25.95 times more probable to identify
ctive compounds from databases than expected by chance. The
alculated GH score value of 0.63, greater than 0.5, indicates a good
eliability of the model.
Despite the small number of molecules so far described as SUB1
nhibitors, the results of this preliminary in silico analysis suggest
hat the SUB1-PHA model could be successfully employed for vir-
ual screening to ﬁnd novel SUB1s inhibitors.
. Conclusion
We  have herein presented the ﬁrst comprehensive approach
or rationalizing the structural requirements for inhibition of SUB1
rom different Plasmodium species. We  built up homology mod-
ls of SUB1 from different Plasmodium species adopting multiple
emplate-based alignments. The available X-ray structures and our
omology models were used for Molecular Docking studies using
he potent PfSUB1 inhibitors 1 and 2 previously developed by
s for our inclusive computational analysis. Computational stud-
es were validated by in vitro testing, indicating our compounds
s the most potent pan-SUB1 inhibitors reported to date. On the
asis of the rational approach described here, we  have predicted
nd experimentally demonstrated that inhibitors 1 and 2 are able
o potently inhibit SUB1 enzymes of the most important human
alaria pathogens, conﬁrming that the development of pan-SUB1
nhibitors is a feasible task [11]. We  also developed and vali-
ated a comprehensive pharmacophore model (SUB1-PHA), and
e are conﬁdent that it will be useful for the rational design of
ptimized pan-inhibitors by adopting fragment-based techniques
nd/or for a classical virtual screening campaign. Taken together,
hese ﬁndings pave the way to the development of a novel class of
an-antimalarial agents for human infections by targeting serine
rotease SUB1. It is also worth noting that, based on the studies
eported here, compounds designed on the basis of endogenous
ubstrates of PfSUB1 (such as 1 and 2) would not be expected to
ossess similar activity against P. berghei,  P. chabaudi or P. yoelii.
s a consequence, suitable animal models of the disease should
e developed in the future to investigate the in vivo antimalarial
otential of substrate-based inhibitors of SUB1 and for progressing
hem into the drug discovery pipeline.
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